Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and at last count has given invited lectures in 33 countries.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).

Disclosures

CONSULTANT: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Moyvant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.

Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio.

 

Recent Contributions to PracticeUpdate:

  1. Intensification of Androgen Blockade in Men With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer
  2. 2023 Top Story in Prostate Cancer: PARP Inhibition Moves Forward
  3. Digital Pathology–Based Multimodal AI-Derived Model in Localized Metastatic Prostate Cancer
  4. Refining Risk Stratification in Patients Undergoing Radiotherapy and Long-Term ADT for High-Risk/Locally Advanced Prostate Cancer
  5. Pembrolizumab Plus Enzalutamide and ADT for Patient With mHSPC
  6. AMG 509 (Xaluritamig) in Patients With mCRPC
  7. RADICALS RT: Timing of Adjuvant Radiotherapy Following Radical Prostatectomy
  8. ENZA-p: Enzalutamide and 177Lu–PSMA-617 in Patients With Poor-Risk mCRPC
  9. PSMAfore: 177Lu–PSMA-617 in Taxane-Naïve Patients With Metastatic Castration-Resistant Prostate Cancer
  10. Addition of Docetaxel to Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Most Read This Week

Recently Updated